KR20010101151A - 에키노칸딘 시클로펩티드 화합물의 정제 - Google Patents
에키노칸딘 시클로펩티드 화합물의 정제 Download PDFInfo
- Publication number
- KR20010101151A KR20010101151A KR1020017007161A KR20017007161A KR20010101151A KR 20010101151 A KR20010101151 A KR 20010101151A KR 1020017007161 A KR1020017007161 A KR 1020017007161A KR 20017007161 A KR20017007161 A KR 20017007161A KR 20010101151 A KR20010101151 A KR 20010101151A
- Authority
- KR
- South Korea
- Prior art keywords
- acetic acid
- group
- mixture
- product
- aldehyde
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 32
- 238000000746 purification Methods 0.000 title abstract description 12
- 108010049047 Echinocandins Proteins 0.000 title description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims abstract description 128
- 238000000034 method Methods 0.000 claims abstract description 56
- 238000000855 fermentation Methods 0.000 claims abstract description 26
- 230000004151 fermentation Effects 0.000 claims abstract description 25
- 230000008569 process Effects 0.000 claims abstract description 24
- 239000000047 product Substances 0.000 claims abstract description 23
- 239000000203 mixture Substances 0.000 claims abstract description 19
- 239000006227 byproduct Substances 0.000 claims abstract description 18
- 125000003277 amino group Chemical group 0.000 claims abstract description 17
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 14
- 108010069514 Cyclic Peptides Proteins 0.000 claims abstract description 12
- 102000001189 Cyclic Peptides Human genes 0.000 claims abstract description 12
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 10
- 238000004366 reverse phase liquid chromatography Methods 0.000 claims abstract description 5
- 229920005989 resin Polymers 0.000 claims description 18
- 239000011347 resin Substances 0.000 claims description 18
- 239000011148 porous material Substances 0.000 claims description 13
- 239000002245 particle Substances 0.000 claims description 12
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims description 11
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 125000003118 aryl group Chemical group 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 9
- 239000012501 chromatography medium Substances 0.000 claims description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 125000003342 alkenyl group Chemical group 0.000 claims description 5
- 125000000304 alkynyl group Chemical group 0.000 claims description 5
- 125000001072 heteroaryl group Chemical group 0.000 claims description 5
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 claims description 4
- CHRJZRDFSQHIFI-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;styrene Chemical group C=CC1=CC=CC=C1.C=CC1=CC=CC=C1C=C CHRJZRDFSQHIFI-UHFFFAOYSA-N 0.000 claims description 4
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims description 4
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims description 4
- 229920000620 organic polymer Polymers 0.000 claims description 4
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 3
- UJTTUOLQLCQZEA-UHFFFAOYSA-N 9h-fluoren-9-ylmethyl n-(4-hydroxybutyl)carbamate Chemical compound C1=CC=C2C(COC(=O)NCCCCO)C3=CC=CC=C3C2=C1 UJTTUOLQLCQZEA-UHFFFAOYSA-N 0.000 claims description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 239000002609 medium Substances 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 238000001212 derivatisation Methods 0.000 abstract description 6
- 238000000926 separation method Methods 0.000 abstract description 5
- 238000002156 mixing Methods 0.000 abstract description 3
- 238000001179 sorption measurement Methods 0.000 abstract 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 70
- 238000010828 elution Methods 0.000 description 33
- 235000010633 broth Nutrition 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- -1 hydrocarbon radical Chemical class 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 229910004373 HOAc Inorganic materials 0.000 description 11
- 238000004587 chromatography analysis Methods 0.000 description 9
- FAUOJMHVEYMQQG-HVYQDZECSA-N echinocandin B Chemical compound C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3C[C@H](C)[C@H](O)[C@H]3C(=O)N[C@H](O)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCC\C=C/C\C=C/CCCCC)[C@@H](C)O)=CC=C(O)C=C1 FAUOJMHVEYMQQG-HVYQDZECSA-N 0.000 description 9
- 238000004007 reversed phase HPLC Methods 0.000 description 9
- 239000003960 organic solvent Substances 0.000 description 8
- 108010062092 echinocandin B Proteins 0.000 description 7
- 230000020176 deacylation Effects 0.000 description 6
- 238000005947 deacylation reaction Methods 0.000 description 6
- 239000003607 modifier Substances 0.000 description 6
- 229930014626 natural product Natural products 0.000 description 6
- 229910019142 PO4 Inorganic materials 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 5
- 239000010452 phosphate Substances 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 229930195733 hydrocarbon Natural products 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 238000004811 liquid chromatography Methods 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000000356 contaminant Substances 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- KAPLTEIQCKDUAT-UHFFFAOYSA-N ac1la431 Chemical compound N1C(=O)C2CC(O)CN2C(=O)C(C(C)O)NC(=O)C(NC(=O)CCCCCCCCCCCCCCC)CC(O)C(O)NC(=O)C2C(O)C(C)CN2C(=O)C(C(O)CC(N)=O)NC(=O)C1C(O)C(O)C1=CC=C(O)C(OS(O)(=O)=O)=C1 KAPLTEIQCKDUAT-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 229940001584 sodium metabisulfite Drugs 0.000 description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- 241000187840 Actinoplanes utahensis Species 0.000 description 1
- 241000351920 Aspergillus nidulans Species 0.000 description 1
- DFQUSLQYURJBIT-MFKXNLKNSA-N C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3C[C@H](C)[C@H](O)[C@H]3C(=O)N[C@H](O)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCCC(C)CC(C)CC)[C@H](O)CC(N)=O)=CC=C(O)C=C1 Chemical compound C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3C[C@H](C)[C@H](O)[C@H]3C(=O)N[C@H](O)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCCC(C)CC(C)CC)[C@H](O)CC(N)=O)=CC=C(O)C=C1 DFQUSLQYURJBIT-MFKXNLKNSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- CWLQUGTUXBXTLF-UHFFFAOYSA-N N-methyl-L-proline monohydrate Natural products CN1CCCC1C(O)=O CWLQUGTUXBXTLF-UHFFFAOYSA-N 0.000 description 1
- CWLQUGTUXBXTLF-YFKPBYRVSA-N N-methylproline Chemical compound CN1CCC[C@H]1C(O)=O CWLQUGTUXBXTLF-YFKPBYRVSA-N 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108010045495 WF 11899A Proteins 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000002431 aminoalkoxy group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000012045 crude solution Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 108010062096 echinocandin C Proteins 0.000 description 1
- NZZDHXBKVFENNY-YBPCKFEPSA-N echinocandin c Chemical compound C([C@@H](O)[C@H]1C(=O)N[C@H](C(=O)N2C[C@H](C)[C@H](O)[C@H]2C(=O)N[C@H](O)[C@H](O)C[C@@H](C(N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)N1)[C@@H](C)O)=O)NC(=O)CCCCCCC\C=C/C\C=C/CCCCC)[C@@H](C)O)C1=CC=C(O)C=C1 NZZDHXBKVFENNY-YBPCKFEPSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000012156 elution solvent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 230000005661 hydrophobic surface Effects 0.000 description 1
- 125000005191 hydroxyalkylamino group Chemical group 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000011045 prefiltration Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- OGNAOIGAPPSUMG-UHFFFAOYSA-N spiro[2.2]pentane Chemical compound C1CC11CC1 OGNAOIGAPPSUMG-UHFFFAOYSA-N 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 239000010891 toxic waste Substances 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11152498P | 1998-12-09 | 1998-12-09 | |
| US60/111,524 | 1998-12-09 | ||
| PCT/US1999/029008 WO2000034315A2 (en) | 1998-12-09 | 1999-12-08 | Purification of echinocandin cyclopeptide compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20010101151A true KR20010101151A (ko) | 2001-11-14 |
Family
ID=22339024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020017007161A Withdrawn KR20010101151A (ko) | 1998-12-09 | 1999-12-08 | 에키노칸딘 시클로펩티드 화합물의 정제 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US6506726B1 (https=) |
| EP (1) | EP1137663B1 (https=) |
| JP (1) | JP2003511345A (https=) |
| KR (1) | KR20010101151A (https=) |
| CN (1) | CN1337968A (https=) |
| AT (1) | ATE338059T1 (https=) |
| AU (1) | AU766091B2 (https=) |
| BR (1) | BR9916101A (https=) |
| CA (1) | CA2353930A1 (https=) |
| DE (1) | DE69933046T2 (https=) |
| DK (1) | DK1137663T3 (https=) |
| ES (1) | ES2272096T3 (https=) |
| IL (1) | IL143563A0 (https=) |
| PT (1) | PT1137663E (https=) |
| RU (1) | RU2001118849A (https=) |
| WO (1) | WO2000034315A2 (https=) |
| ZA (1) | ZA200104621B (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6743777B1 (en) * | 1992-03-19 | 2004-06-01 | Eli Lilly And Company | Cyclic peptide antifungal agents and process for preparation thereof |
| HK1040062A1 (zh) * | 1999-03-03 | 2002-05-24 | Eli Lilly And Company | 含有成胶束表面活性剂的棘白菌素药物配方 |
| ATE248187T1 (de) | 1999-03-03 | 2003-09-15 | Lilly Co Eli | Echinocandin-kohlenhydrate-komplexe |
| HK1040369A1 (zh) | 1999-03-03 | 2002-06-07 | Eli Lilly And Company | 制备药物口服ecb配方和组合物的方法 |
| AU767956B2 (en) | 1999-03-03 | 2003-11-27 | Eli Lilly And Company | Formation and anion-exchange of crystalline echinocandin ammonium salts |
| US6991800B2 (en) * | 2002-06-13 | 2006-01-31 | Vicuron Pharmaceuticals Inc. | Antifungal parenteral products |
| JP5112060B2 (ja) * | 2004-06-29 | 2013-01-09 | リライアンス ライフ サイエンシーズ プライベイト リミテッド | ウイルス安全性生物学的流体の調製のための方法 |
| DE102004060750A1 (de) | 2004-12-15 | 2006-07-13 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur Deacylierung von Lipopeptiden |
| TW200826957A (en) * | 2006-10-16 | 2008-07-01 | Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag | Purification processes for echinocandin-type compounds |
| US9394340B2 (en) | 2009-03-24 | 2016-07-19 | Cadila Healthcare Limited | Purification process for lipopeptides |
| CN102219832B (zh) | 2010-04-15 | 2013-08-21 | 上海天伟生物制药有限公司 | 一种氮杂环六肽或其盐的纯化方法 |
| CN102336817B (zh) * | 2010-07-16 | 2016-06-15 | 浙江震元制药有限公司 | 棘球白素b母核的分离方法 |
| ES2581562T3 (es) | 2010-09-29 | 2016-09-06 | Shanghai Techwell Biopharmaceutical Co., Ltd | Procedimiento para purificar compuestos lipopeptídicos cíclicos o sales de los mismos |
| CN102443050B (zh) * | 2010-09-30 | 2014-06-04 | 上海天伟生物制药有限公司 | 一种环脂肽化合物或其盐的纯化方法 |
| CN102153616A (zh) * | 2010-12-27 | 2011-08-17 | 浙江海正药业股份有限公司 | 一种环己肽类化合物及其盐的分离纯化方法 |
| WO2012119065A2 (en) | 2011-03-03 | 2012-09-07 | Seachaid Pharmaceuticals, Inc. | Antifungal agents and uses thereof |
| WO2012143293A1 (en) * | 2011-04-20 | 2012-10-26 | Xellia Pharmaceuticals Aps | Method for purification of micafungin |
| CN102952178B (zh) * | 2011-08-24 | 2016-04-27 | 华北制药集团新药研究开发有限责任公司 | 一种高纯度棘白霉素类化合物的制备方法 |
| SI3677252T1 (sl) | 2012-03-19 | 2024-02-29 | Cidara Therapeutics, Inc. | Sheme odmerjanja za spojine iz razreda ehinokandinov |
| CN103483427A (zh) * | 2012-06-09 | 2014-01-01 | 浙江海正药业股份有限公司 | 一种棘白菌素类化合物的纯化方法 |
| CN103910783B (zh) * | 2014-04-23 | 2016-07-06 | 华北制药集团新药研究开发有限责任公司 | 一种高纯度棘白霉素b母核的制备方法 |
| PL3058958T3 (pl) | 2015-02-23 | 2019-02-28 | Selectchemie Ag | Kompozycja anidulafunginy |
| CN108883152A (zh) | 2016-01-08 | 2018-11-23 | 奇达拉治疗公司 | 防止和治疗肺孢子虫感染的方法 |
| MA43825A (fr) | 2016-03-16 | 2021-04-07 | Cidara Therapeutics Inc | Schémas posologiques pour le traitement d'infections fongiques |
| CN106248857A (zh) * | 2016-07-15 | 2016-12-21 | 广西医科大学 | 利用薄层层析快速检测植物环肽的方法 |
| JP7779651B2 (ja) | 2017-07-12 | 2025-12-03 | ナップ ファーマシューティカル グループ リミテッド | 真菌感染症の処置のための組成物及び方法 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4304716A (en) | 1979-12-13 | 1981-12-08 | Eli Lilly And Company | S 31794/F-1 Nucleus |
| US4293489A (en) | 1979-12-13 | 1981-10-06 | Eli Lilly And Company | Derivatives of A-30912A nucleus |
| US4320052A (en) | 1979-12-13 | 1982-03-16 | Eli Lilly And Company | Derivatives of A-30912A nucleus |
| US4293482A (en) | 1979-12-13 | 1981-10-06 | Eli Lilly And Company | A-30912A Nucleus |
| US4874843A (en) | 1987-12-03 | 1989-10-17 | Eli Lilly And Company | Chromatographic purification process |
| EP0294990A3 (en) | 1987-06-10 | 1990-05-09 | Eli Lilly And Company | Chromatographic purification process |
| US5166135A (en) | 1988-09-12 | 1992-11-24 | Merck & Company, Inc. | Method for the control of pneumocystis carinii |
| DK173802B1 (da) | 1988-09-12 | 2001-11-05 | Merck & Co Inc | Præparat til behandling af Pneumocystis carinii infeksioner og anvendelse af et cyclohexapeptid til fremstilling af et lægemiddel mod Pneumocystis carinii infektioner |
| US5310726A (en) | 1990-03-19 | 1994-05-10 | Merck & Co., Inc. | Lipopeptide compounds |
| IL98349A (en) | 1990-06-07 | 1995-05-26 | Lilly Co Eli | Diphylase lipopeptide |
| IL98506A (en) | 1990-06-18 | 1996-09-12 | Fujisawa Pharmaceutical Co | Cyclic peptide antibiotics processes for the preparation thereof and pharmaceutical compositions containing them |
| US5965525A (en) | 1992-03-19 | 1999-10-12 | Eli Lilly And Company | Cyclic peptide antifungal agents |
| MY136593A (en) | 1992-03-19 | 2008-10-31 | Lilly Co Eli | Cyclic peptide antifungal agents and process for preparation thereof |
| US5541160A (en) | 1994-04-04 | 1996-07-30 | Merck & Co., Inc. | Antifungal and anti-pneumocystis compounds, compositions containing such compounds, and methods of use |
| US5646111A (en) | 1995-04-07 | 1997-07-08 | Eli Lilly And Company | Cyclic peptide antifungal Agents |
| US5618787A (en) | 1995-05-26 | 1997-04-08 | Eli Lilly And Company | Cyclic peptide antifungal agents |
| US5786325A (en) | 1995-05-26 | 1998-07-28 | Eli Lilly And Company | Cyclic peptide antifungal agents and methods of making and using |
| US5652213A (en) | 1995-05-26 | 1997-07-29 | Eli Lilly And Company | Cyclic peptide antifungal agents |
| US5629290A (en) | 1995-05-26 | 1997-05-13 | Eli Lilly And Company | Cyclic peptide antifungal agents |
| US5629289A (en) | 1995-07-25 | 1997-05-13 | Eli Lilly And Company | Cyclic peptide antifungal agents |
| EP0881907A4 (en) | 1996-02-01 | 2000-05-10 | Lilly Co Eli | FUNGICIDES IN THE FORM OF CYCLIC PEPTIDES |
| US5696084A (en) | 1996-08-16 | 1997-12-09 | Abbott Laboratories | Amino-lipopetide antifungal agents |
| WO1999006062A1 (en) | 1997-08-04 | 1999-02-11 | Eli Lilly And Company | Cyclic peptide antifungal agents |
| CA2255140A1 (en) | 1997-12-23 | 1999-06-23 | Eli Lilly And Company | Echinocandin binding domain of 1,3-.beta.-glucan synthase |
| US6323176B1 (en) | 1998-02-25 | 2001-11-27 | Eli Lilly And Company | Cyclic peptide antifungal agents |
| ATE287899T1 (de) | 1998-08-20 | 2005-02-15 | Lilly Co Eli | Verfahren zur herstellung von ring-modifizierten zyklischen peptidanalogen |
| CA2340647A1 (en) | 1998-08-28 | 2000-03-09 | Eli Lilly And Company | Reversible boronate complexes of 1,2-cis-diol cyclic-peptides |
| WO2000024694A1 (en) | 1998-10-28 | 2000-05-04 | Eli Lilly And Company | Photochemical process for making 1-deoxy-2-keto derivatives |
| AU767357B2 (en) | 1998-12-16 | 2003-11-06 | Eli Lilly And Company | Cyclic peptide antifungal agents |
| AU2189500A (en) | 1998-12-16 | 2000-07-03 | Eli Lilly And Company | Cyclic peptide antifungal agents having a sugar substituent |
| HK1040369A1 (zh) | 1999-03-03 | 2002-06-07 | Eli Lilly And Company | 制备药物口服ecb配方和组合物的方法 |
| ATE248187T1 (de) | 1999-03-03 | 2003-09-15 | Lilly Co Eli | Echinocandin-kohlenhydrate-komplexe |
| AU767956B2 (en) | 1999-03-03 | 2003-11-27 | Eli Lilly And Company | Formation and anion-exchange of crystalline echinocandin ammonium salts |
| HK1040062A1 (zh) | 1999-03-03 | 2002-05-24 | Eli Lilly And Company | 含有成胶束表面活性剂的棘白菌素药物配方 |
-
1999
- 1999-12-08 DK DK99965156T patent/DK1137663T3/da active
- 1999-12-08 AT AT99965156T patent/ATE338059T1/de not_active IP Right Cessation
- 1999-12-08 JP JP2000586757A patent/JP2003511345A/ja not_active Abandoned
- 1999-12-08 DE DE69933046T patent/DE69933046T2/de not_active Expired - Fee Related
- 1999-12-08 CA CA002353930A patent/CA2353930A1/en not_active Abandoned
- 1999-12-08 ES ES99965156T patent/ES2272096T3/es not_active Expired - Lifetime
- 1999-12-08 KR KR1020017007161A patent/KR20010101151A/ko not_active Withdrawn
- 1999-12-08 PT PT99965156T patent/PT1137663E/pt unknown
- 1999-12-08 US US09/857,924 patent/US6506726B1/en not_active Expired - Fee Related
- 1999-12-08 WO PCT/US1999/029008 patent/WO2000034315A2/en not_active Ceased
- 1999-12-08 EP EP99965156A patent/EP1137663B1/en not_active Expired - Lifetime
- 1999-12-08 AU AU31132/00A patent/AU766091B2/en not_active Ceased
- 1999-12-08 RU RU2001118849/04A patent/RU2001118849A/ru not_active Application Discontinuation
- 1999-12-08 CN CN99815515A patent/CN1337968A/zh active Pending
- 1999-12-08 IL IL14356399A patent/IL143563A0/xx unknown
- 1999-12-08 BR BR9916101-0A patent/BR9916101A/pt not_active IP Right Cessation
-
2001
- 2001-06-06 ZA ZA200104621A patent/ZA200104621B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1137663B1 (en) | 2006-08-30 |
| ES2272096T3 (es) | 2007-04-16 |
| IL143563A0 (en) | 2002-04-21 |
| CN1337968A (zh) | 2002-02-27 |
| RU2001118849A (ru) | 2003-08-10 |
| EP1137663A2 (en) | 2001-10-04 |
| BR9916101A (pt) | 2002-06-04 |
| US6506726B1 (en) | 2003-01-14 |
| ZA200104621B (en) | 2002-06-06 |
| DE69933046D1 (de) | 2006-10-12 |
| PT1137663E (pt) | 2006-12-29 |
| CA2353930A1 (en) | 2000-06-15 |
| WO2000034315A3 (en) | 2000-12-28 |
| WO2000034315A2 (en) | 2000-06-15 |
| AU3113200A (en) | 2000-06-26 |
| WO2000034315A8 (en) | 2000-10-26 |
| ATE338059T1 (de) | 2006-09-15 |
| DE69933046T2 (de) | 2007-09-13 |
| DK1137663T3 (da) | 2007-01-08 |
| JP2003511345A (ja) | 2003-03-25 |
| AU766091B2 (en) | 2003-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU766091B2 (en) | Purification of echinocandin cyclopeptide compounds | |
| JP4063497B2 (ja) | エキノカンジンアンモニウム塩結晶の形成およびアニオン交換 | |
| CA1315229C (en) | Chromatographic purification process | |
| EP2076528B1 (en) | Purification processes of echinocandin-type compounds | |
| KR960002868B1 (ko) | 글리코펩티드 항생물질의 회수 방법 | |
| US4874843A (en) | Chromatographic purification process | |
| JP4173124B2 (ja) | バンコマイシン塩酸塩の精製方法 | |
| AU613640B2 (en) | Chromatographic purification process | |
| AU2004200026A1 (en) | Purification of echinocandin cyclopeptide compounds | |
| MXPA01005688A (en) | Purification of echinocandin cyclopeptide compounds | |
| KR101844833B1 (ko) | 테이코플라닌 정제방법 | |
| KR100419707B1 (ko) | 분취용 역상 고압 액체 크로마토그래피를 이용한반코마이신의 정제방법 | |
| AU2004200741A1 (en) | Formation and anion-exchange of crystalline echinocandin ammonium salts | |
| MXPA01008787A (en) | Formation and anion-exchange of crystalline echinocandin ammonium salts | |
| HU181731B (en) | Process for the purification of 6-/d-2-/d-2-amino-3-n-methyl-carbamoyl-propionamido/-2-p-hydroxy-phenyl-acetamido/-penicillanic acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20010608 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |